142 related articles for article (PubMed ID: 22149874)
1. HER2 therapy--an abundance of riches.
Gradishar WJ
N Engl J Med; 2012 Jan; 366(2):176-8. PubMed ID: 22149874
[No Abstract] [Full Text] [Related]
2. Pertuzumab plus trastuzumab in metastatic breast cancer.
Revannasiddaiah S; Seam R; Gupta M
N Engl J Med; 2012 Apr; 366(14):1349; author reply 1349-50. PubMed ID: 22475604
[No Abstract] [Full Text] [Related]
3. Pertuzumab plus trastuzumab in metastatic breast cancer.
Li-Wan-Po A
N Engl J Med; 2012 Apr; 366(14):1348-9; author reply 1349-50. PubMed ID: 22475603
[No Abstract] [Full Text] [Related]
4. Pertuzumab plus trastuzumab in metastatic breast cancer.
Şendur MA; Aksoy S; Zengin N
N Engl J Med; 2012 Apr; 366(14):1348; author reply 1349-50. PubMed ID: 22475602
[No Abstract] [Full Text] [Related]
5. Dual HER2 blockade slows metastatic breast cancer.
Bender E
Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
[No Abstract] [Full Text] [Related]
6. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
[No Abstract] [Full Text] [Related]
7. [Pertuzumab+trastuzumab+DTX therapy].
Maejima A; Tamura K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():553-7. PubMed ID: 25831821
[No Abstract] [Full Text] [Related]
8. CLEOPATRA holds strong in final analysis.
Cancer Discov; 2014 Dec; 4(12):OF3. PubMed ID: 25477120
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Abair T; O'Shaughnessy J
Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
[No Abstract] [Full Text] [Related]
10. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing in patients with breast cancer.
Dixon JM; Wilson V; Verrill M; Symmans WF
BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
[No Abstract] [Full Text] [Related]
12. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.
Gullo G; Zuradelli M; Sclafani F; Santoro A; Crown J
Ann Oncol; 2012 Aug; 23(8):2204-2205. PubMed ID: 22767587
[No Abstract] [Full Text] [Related]
13. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Goel S; Winer EP
Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
[No Abstract] [Full Text] [Related]
14. Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer.
Luen SJ; Loi S
Chin Clin Oncol; 2018 Feb; 7(1):2. PubMed ID: 29156891
[No Abstract] [Full Text] [Related]
15. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers.
Huober J; Baumann M; Rochlitz C; Aebi S; Güth U; von Moos R; Müller A; von Rohr L; Widmer I; Thürlimann B
Oncology; 2011; 81(3-4):160-6. PubMed ID: 22041972
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy herceptin+taxotere/Herceptin+navelbine].
Meden H
Onkologie; 2002 Dec; 25 Suppl 5():15-6. PubMed ID: 23573614
[No Abstract] [Full Text] [Related]
19. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
